Brilliant!

By Vitaliy N. Katsenelson, CFA I wrote this article on the impact that Wal-Mart’s (WMT) brilliant (I think it’s a stroke of genius) actions will have on CVS (CVS) and Walgreens (WAG) – which is not much, unless grocery stores will follow WMT’s lead, possibly diminishing my “convenience” argument. I failed to mention in the…

By Vitaliy N. Katsenelson, CFA

I wrote this article on the impact that Wal-Mart’s (WMT) brilliant (I think it’s a stroke of genius) actions will have on CVS (CVS) and Walgreens (WAG) – which is not much, unless grocery stores will follow WMT’s lead, possibly diminishing my “convenience” argument.

I failed to mention in the article that at times insurance co-pay for generic drugs will exceed $4 that Wal-Mart is offering. In my experience most copays for generic run at about $5-$10. So will consumers want to go to Wal-Mart to save from $1 to $6 on generic copay. I’d bet that a very small minority would. The brilliance of WMT’s action is that neither WAG or CVS can follow its strategy otherwise they’ll jeopardize reimbursement rates from the insurance companies.

Wal-Mart actions were not really focused on WAG or CVS since most of their customers have insurance, they were directed towards the uninsured consumers. A bigger question, will insurance companies try to exert pressure on pharmacy retailers to follow WMT’s pricing – they may try but I don’t believe they’ll be successful.

(see original article for position disclosure)

Please read the following important disclosure here.

Related Articles

Why I No Longer Mind Losing an Argument

Why I No Longer Mind Losing an Argument

Reflecting on my experience with Dale Carnegie's book, I share how it transformed my approach to criticism and debate, and why I no longer mind losing an argument.

How do I get any research done since I travel a lot?

I get asked at times: How do I get any research done since I travel a lot? To answer this question, I need to explain how we do research.
The Growing Pains of Maturity

The Growing Pains of Maturity

Many times, we bought because they were in their “junior year”; this is what made them undervalued. Our research led us to the conclusion that their difficulties were transitory and that as they matured the market would revalue them.
What is the Value of Apple? How do we evaluate risk?

What is the Value of Apple? How do we evaluate risk?

Today I will share the Q&A section of the letter. Every time I am almost finished with the client letter, I ask clients to send me any questions they have about their portfolio or other topics. I answer these questions in the Q&A section.

Leave a Comment